Document 0262
 DOCN  M9590262
 TI    Ketoconazole shampoo in the treatment of seborrhoeic dermatitis in
       patients with HIV infection.
 DT    9509
 AU    Duncombe C; Bloch M; Quan D; Holdsworth House General Practice,
       Darlinghurst NSW.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:261 (unnumbered poster).
       Unique Identifier : AIDSLINE ASHM6/95291837
 AB    STUDY OBJECTIVES: To assess the safety and efficacy of Ketoconazole
       applied as a 2% shampoo in the treatment of seborrhoeic dermatitis in
       patients with concomitant HIV infection. METHODOLOGY: 46 HIV positive
       patients with moderate to severe facial and scalp seb. derm. applied
       Ketoconazole as a 2% shampoo to the scalp massaging the lather over the
       face and other affected areas leaving contact with the skin for five
       minutes. Treatment was for three consecutive days then twice weekly for
       four weeks. SUMMARY OF RESULTS: 31 patients reported complete resolution
       of scaling, erythema and itch. 13 patients reported a marked improvement
       in symptoms. Two patients reported a moderate improvement. There were no
       adverse events reported and all participants completed the four week
       course of treatment. CONCLUSION: Seborrhoeic dermatitis is a common
       condition in people with HIV infection. There appears to be a causative
       relationship between the yeast Pityrosporum and seborrhoeic dermatitis,
       hence the rationale for using the topical anti-fungal agent
       Ketoconazole. The shampoo as a delivery agent is 'patient-friendly' and
       compliance was good. Ketoconazole shampoo is an effective and safe
       treatment for seborrhoeic dermatitis. Immunosuppressed patients often
       will need maintenance therapy.
 DE    Administration, Topical  AIDS-Related Opportunistic Infections/*DRUG
       THERAPY  Dermatitis, Seborrheic/*DRUG THERAPY  *Hair Preparations  Human
       Ketoconazole/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).